PRECISION siRNA GENE SILENCING

Silencing Disease
at the Genetic Source

Engineering next-generation siRNA therapeutics that address the root cause of disease — starting with androgenetic alopecia, the most common form of hair loss.

Precise

Sequence-specific siRNA silences disease-driving genes via the RISC pathway — durable, precise knockdown with no genome editing.

Local

Designed for local administration to the scalp, focusing therapeutic activity at the hair follicle and limiting systemic exposure.

Regrow

Our lead program, SGA-001, addresses the biological drivers of follicle miniaturization, with the goal of restoring healthy hair growth.

About NEXOR

Targeting Unmet Medical Needs with RNA Precision

NEXOR THERAPEUTICS INC. is building siRNA-based medicines that silence disease-causing genes with high specificity, enabling new treatments where none currently exist. Our approach combines validated gene targets, purpose-built delivery chemistry, and rigorous preclinical science. Our lead program, SGA-001 for androgenetic alopecia, is developed through our affiliate SILGENIX ADI LLC.

siRNA Gene Silencing

Sequence-specific mRNA degradation via the RISC pathway — durable knockdown of validated disease targets

Validated Disease Targets

Mechanistically grounded programs with clear preclinical-to-clinical translation pathways

Robust IP Foundation

U.S. provisional patent application filed with the USPTO (patent pending)

Get in Touch

Inquiries Welcome

For licensing or research partnership inquiries, please reach out directly.

[email protected]